InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research report issued on Wednesday. The brokerage set a “sell” rating on the stock.

InspireMD Price Performance

Shares of NYSE:NSPR opened at $1.98 on Wednesday. The company has a market capitalization of $46.22 million, a P/E ratio of -1.83 and a beta of 0.84. InspireMD has a 1 year low of $1.00 and a 1 year high of $3.85. The business’s 50 day simple moving average is $2.41 and its 200 day simple moving average is $2.69.

InspireMD (NYSE:NSPR) last issued its quarterly earnings results on Wednesday, March 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. The business had revenue of $1.76 million for the quarter, compared to the consensus estimate of $1.65 million. InspireMD had a negative return on equity of 55.71% and a negative net margin of 320.97%. During the same quarter in the prior year, the business posted ($0.60) earnings per share. On average, sell-side analysts anticipate that InspireMD will post -0.61 EPS for the current fiscal year.

Institutional Investors Weigh In On InspireMD

An institutional investor recently bought a new position in InspireMD stock. Avestar Capital LLC bought a new stake in InspireMD, Inc. (NYSE:NSPR) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 20,000 shares of the company’s stock, valued at approximately $65,000. Avestar Capital LLC owned approximately 0.09% of InspireMD as of its most recent filing with the SEC. 44.78% of the stock is owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.